Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab add-on therapy for moderate-to-severe active ulcerative colitis
2011-004812-40Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Tralokinumab add-on therapy with Placebo add-on therapy (2 arms). Primary endpoint: Clinical response at week 8. Started Nov 2011; status: completed.
02
Drugs
tralokinumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2011-004812-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004812-40.